From early innovations to commercial triumphs: One viral vector partner for every stage of gene therapy development


Viral vector gene therapies have the potential to treat a diverse array of diseases that were once considered untreatable. From genetic disorders to rare cancers and infectious diseases, viral vectors serve as tools for delivering therapeutic genes directly to target cells, enabling precise interventions. Despite those benefits, viral vector development and manufacturing present formidable challenges. These include process and analytical development, scaling up from clinical to commercial, sterile fill-finish services, and navigating regulatory requirements, as well as ensuring a reliable supply chain.

Here's where a contract development and manufacturing organization (CDMO) can help. With specialized expertise, state-of-the-art facilities, and standardized processes, CDMOs offer comprehensive support from pre-clinical to commercial manufacturing. Our new article explores the partnership needs of two companies, NysnoBio and bluebird bio, who are currently developing treatments for several genetic diseases, including Parkinson’s disease, sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. Specifically, it discusses how a CDMO like Thermo Fisher Scientific can provide support at every stage of gene therapy development, accelerating speed to market.